Triglav Investments D.O.O. Purchases Shares of 15,000 Tempus AI, Inc. $TEM

Triglav Investments D.O.O. purchased a new stake in Tempus AI, Inc. (NASDAQ:TEM) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,000 shares of the company’s stock, valued at approximately $678,000.

Other hedge funds have also modified their holdings of the company. Aberdeen Group plc raised its holdings in shares of Tempus AI by 64.2% in the fourth quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after purchasing an additional 102,878 shares during the last quarter. Pictet Asset Management Holding SA boosted its holdings in Tempus AI by 291.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock worth $2,948,000 after purchasing an additional 36,096 shares during the last quarter. Bogart Wealth LLC grew its position in Tempus AI by 365,087.5% in the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after purchasing an additional 58,414 shares in the last quarter. Bamco Inc. NY increased its stake in Tempus AI by 53.7% in the 3rd quarter. Bamco Inc. NY now owns 263,250 shares of the company’s stock valued at $21,247,000 after buying an additional 92,007 shares during the last quarter. Finally, Alethea Capital Management LLC acquired a new stake in Tempus AI in the 4th quarter valued at $1,863,000. 24.22% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Tempus AI in a research note on Monday, April 13th. They set an “underperform” rating and a $35.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and issued a $80.00 target price on shares of Tempus AI in a research report on Monday, June 1st. Freedom Capital upgraded Tempus AI to a “hold” rating in a report on Tuesday, June 30th. Guggenheim decreased their price target on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research note on Monday, June 1st. Nine analysts have rated the stock with a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $68.54.

Tempus AI Price Performance

TEM stock opened at $58.23 on Monday. Tempus AI, Inc. has a fifty-two week low of $41.73 and a fifty-two week high of $104.32. The company has a debt-to-equity ratio of 2.96, a current ratio of 3.31 and a quick ratio of 3.15. The stock has a market capitalization of $10.46 billion, a price-to-earnings ratio of -33.85 and a beta of 3.46. The business’s fifty day moving average price is $51.29 and its two-hundred day moving average price is $54.27.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. During the same quarter in the previous year, the business posted ($0.24) earnings per share. Tempus AI’s quarterly revenue was up 36.1% on a year-over-year basis. On average, equities analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Insider Buying and Selling at Tempus AI

In related news, CFO James William Rogers sold 11,529 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $55.00, for a total transaction of $634,095.00. Following the sale, the chief financial officer owned 114,866 shares of the company’s stock, valued at $6,317,630. This represents a 9.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 166,250 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $46.70, for a total value of $7,763,875.00. Following the transaction, the chief executive officer owned 8,808,533 shares in the company, valued at approximately $411,358,491.10. This trade represents a 1.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 616,043 shares of company stock valued at $31,748,593 over the last ninety days. Company insiders own 24.26% of the company’s stock.

Tempus AI Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.